Cargando…

Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia

BACKGROUND: Adult T-cell leukemia (ATL) is a CD4(+) T-cell neoplasm with a poor prognosis. A previous study has shown that there is a strong correlation between the secreted matricellular protein osteopontin (OPN) level and disease severity in ATL patients. Here, we investigated the role of OPN in A...

Descripción completa

Detalles Bibliográficos
Autores principales: Maeda, Naoyoshi, Ohashi, Takashi, Chagan-Yasutan, Haorile, Hattori, Toshio, Takahashi, Yayoi, Harigae, Hideo, Hasegawa, Hiroo, Yamada, Yasuaki, Fujii, Masahiro, Maenaka, Katsumi, Uede, Toshimitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657376/
https://www.ncbi.nlm.nih.gov/pubmed/26597716
http://dx.doi.org/10.1186/s12977-015-0225-x
_version_ 1782402388310622208
author Maeda, Naoyoshi
Ohashi, Takashi
Chagan-Yasutan, Haorile
Hattori, Toshio
Takahashi, Yayoi
Harigae, Hideo
Hasegawa, Hiroo
Yamada, Yasuaki
Fujii, Masahiro
Maenaka, Katsumi
Uede, Toshimitsu
author_facet Maeda, Naoyoshi
Ohashi, Takashi
Chagan-Yasutan, Haorile
Hattori, Toshio
Takahashi, Yayoi
Harigae, Hideo
Hasegawa, Hiroo
Yamada, Yasuaki
Fujii, Masahiro
Maenaka, Katsumi
Uede, Toshimitsu
author_sort Maeda, Naoyoshi
collection PubMed
description BACKGROUND: Adult T-cell leukemia (ATL) is a CD4(+) T-cell neoplasm with a poor prognosis. A previous study has shown that there is a strong correlation between the secreted matricellular protein osteopontin (OPN) level and disease severity in ATL patients. Here, we investigated the role of OPN in ATL pathogenesis and the possible application of anti-OPN monoclonal antibody (mAb) for ATL immunotherapy in NOD/Shi-scid,IL-2Rg(null) (NOG) mice. RESULTS: Subcutaneous inoculation of ATL cell lines into NOG mice increased the plasma level of OPN, which significantly correlated with metastasis of the inoculated cells and survival time. Administration of an SVVYGLR motif-recognizing anti-OPN mAb resulted in inhibition not only of tumor growth but also of tumor invasion and metastasis. The number of fibroblast activating protein-positive fibroblasts was also reduced by this mAb. We then co-inoculated mouse embryonic fibroblasts (MEFs) isolated from wild-type (WT) or OPN knockout mice together with ATL-derived TL-OmI cells into the NOG mice. The mice co-inoculated with WT MEFs displayed a significant decrease in survival relative to those injected with TL-OmI cells alone and the absence of OPN in MEFs markedly improved the survival rate of TL-OmI-inoculated mice. In addition, tumor volume and metastasis were also reduced in the absence of OPN. CONCLUSION: We showed that the xenograft NOG mice model can be a useful system for assessment of the physiological role of OPN in ATL pathogenesis. Using this xenograft model, we found that fibroblast-derived OPN was involved in tumor growth and metastasis, and that this tumor growth and metastasis was significantly suppressed by administration of the anti-OPN mAbs. Our findings will lead to a novel mAb-mediated immunotherapeutic strategy targeting against the interaction of OPN with integrins on the tumor of ATL patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12977-015-0225-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4657376
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46573762015-11-25 Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia Maeda, Naoyoshi Ohashi, Takashi Chagan-Yasutan, Haorile Hattori, Toshio Takahashi, Yayoi Harigae, Hideo Hasegawa, Hiroo Yamada, Yasuaki Fujii, Masahiro Maenaka, Katsumi Uede, Toshimitsu Retrovirology Research BACKGROUND: Adult T-cell leukemia (ATL) is a CD4(+) T-cell neoplasm with a poor prognosis. A previous study has shown that there is a strong correlation between the secreted matricellular protein osteopontin (OPN) level and disease severity in ATL patients. Here, we investigated the role of OPN in ATL pathogenesis and the possible application of anti-OPN monoclonal antibody (mAb) for ATL immunotherapy in NOD/Shi-scid,IL-2Rg(null) (NOG) mice. RESULTS: Subcutaneous inoculation of ATL cell lines into NOG mice increased the plasma level of OPN, which significantly correlated with metastasis of the inoculated cells and survival time. Administration of an SVVYGLR motif-recognizing anti-OPN mAb resulted in inhibition not only of tumor growth but also of tumor invasion and metastasis. The number of fibroblast activating protein-positive fibroblasts was also reduced by this mAb. We then co-inoculated mouse embryonic fibroblasts (MEFs) isolated from wild-type (WT) or OPN knockout mice together with ATL-derived TL-OmI cells into the NOG mice. The mice co-inoculated with WT MEFs displayed a significant decrease in survival relative to those injected with TL-OmI cells alone and the absence of OPN in MEFs markedly improved the survival rate of TL-OmI-inoculated mice. In addition, tumor volume and metastasis were also reduced in the absence of OPN. CONCLUSION: We showed that the xenograft NOG mice model can be a useful system for assessment of the physiological role of OPN in ATL pathogenesis. Using this xenograft model, we found that fibroblast-derived OPN was involved in tumor growth and metastasis, and that this tumor growth and metastasis was significantly suppressed by administration of the anti-OPN mAbs. Our findings will lead to a novel mAb-mediated immunotherapeutic strategy targeting against the interaction of OPN with integrins on the tumor of ATL patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12977-015-0225-x) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-24 /pmc/articles/PMC4657376/ /pubmed/26597716 http://dx.doi.org/10.1186/s12977-015-0225-x Text en © Maeda et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Maeda, Naoyoshi
Ohashi, Takashi
Chagan-Yasutan, Haorile
Hattori, Toshio
Takahashi, Yayoi
Harigae, Hideo
Hasegawa, Hiroo
Yamada, Yasuaki
Fujii, Masahiro
Maenaka, Katsumi
Uede, Toshimitsu
Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia
title Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia
title_full Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia
title_fullStr Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia
title_full_unstemmed Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia
title_short Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia
title_sort osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult t-cell leukemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657376/
https://www.ncbi.nlm.nih.gov/pubmed/26597716
http://dx.doi.org/10.1186/s12977-015-0225-x
work_keys_str_mv AT maedanaoyoshi osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia
AT ohashitakashi osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia
AT chaganyasutanhaorile osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia
AT hattoritoshio osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia
AT takahashiyayoi osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia
AT harigaehideo osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia
AT hasegawahiroo osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia
AT yamadayasuaki osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia
AT fujiimasahiro osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia
AT maenakakatsumi osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia
AT uedetoshimitsu osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia